Explore 3 Stock Ideas & Industry Insights Download Free Report

News

IBio (NASDAQ: IBIO), Inc. Revenue Falls to $0.1M as R&D Rises $11.3M

Research and development spending rose approximately $11.3 million to $19.6 million, reflecting higherInvestmentin the company’s development programs.

Vinay Lochav | 31 August 2026

Oruka Therapeutics (NASDAQ: ORKA) Offers Up to $500M Common Stock

Oruka Therapeutics, Inc. (NASDAQ: ORKA) may sell up to $500,000,000 of common stock through TD Cowen, acting as agent or principal. The at-the-market program allows sales from time to time at prices and on terms determined by market conditions. The actual number of shares …

Vinay Lochav | 31 August 2026

Pluri Inc. (NASDAQ: PLUR) Prices $1.50 Share Offering With 2.23M Warrants

Pluri Inc. (NASDAQ: PLUR) agreed to sell 1,200,000 common shares and pre-funded warrants for up to 1,028,940 additional common shares in a registered direct offering. The shares are priced at $1.50 each, while the pre-funded warrants are priced at $1.49999. Pluri expects approximately $2,984,808 …

Vinay Lochav | 31 August 2026

Roivant Sciences (NASDAQ: ROIV) Sets LISRAYA Wholesale Cost at $35,000 After FDA Approval

Roivant Sciences gained U.S. FDA approval for LISRAYA to treat adults with dermatomyositis, with a wholesaleAcquisitioncost of $35,000 for a 30-count bottle of 30 mg tablets. Investors now have a disclosed regulatory milestone and a stated wholesale price for the treatment.Key HighlightsRoivant posted an …

Vinay Lochav | 31 August 2026

Sangamo Therapeutics (OTC: SGMOQ) Agrees to $111M ST-920 Asset Sale

SANGAMO THERAPEUTICS, INC (OTC: SGMOQ). Agreed to sell assets tied primarily to ST-920, its one-time administered AAV gene therapy candidate for Fabry disease, to PTC Therapeutics for $111,000,000 in cash at closing.

Vinay Lochav | 31 August 2026

Shuttle Pharmaceuticals (NASDAQ: SHPH) Must Submit Nasdaq Compliance Plan by October 27

Shuttle Pharmaceuticals facesNasdaqnoncompliance under Listing Rule 5250(c)(1) after delaying its Form 10-Q for the period ended June 30, 2026. The common stock remains listed and tradable for now, but failure to regain compliance could lead to delisting, while the company must submit a corrective …

Vinay Lochav | 31 August 2026

INVO Fertility (NASDAQ: IVF) Details $15M Equity Commitment Ahead of Conference

Arrangement Provides Access to Common-Stock Sales

Vinay Lochav | 31 August 2026

Bone Biologics (NASDAQ: BBLGW) Adds Nasdaq Approval and Adjournment Votes for Sept. 28

Bone Biologics Corp (NASDAQ: BBLGW) will ask shareholders to vote on six proposals at its annual meeting on September 28, 2026, including potential common stock issuance tied to certain warrants and a proposed reverse stock split. The meeting was postponed from August 11, 2026. …

Vinay Lochav | 31 August 2026

Bone Biologics (NASDAQ: BBLGW) Shareholders Face 1-for-2 to 1-for-10 Split Vote

Bone Biologics Corp (NASDAQ: BBLGW) will put a potential reverse stock split before shareholders at its annual meeting on September 28, 2026. The proposed ratio ranges from 1-for-2 to 1-for-10, with the Board holding discretion over the final ratio.

Vinay Lochav | 31 August 2026

Eightco Holdings CEO Buys 50,000 Shares on Open Market

Kevin J. O'Donnell, CEO and Director of Eightco Holdings Inc. (NASDAQ:ORBS), filed a Form 4 on August 31, 2026, disclosing the open-market purchase of 50,000 shares of common stock on August 28, 2026.

Anjali Anand | 31 August 2026
Support

Hi! How can we help you today?

Loading…